Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04701333 · ClinicalTrials.gov registry record · Phase 2
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
A Phase 2 study of Lactation Suppressed, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
- 1
- Study location
NCT04701333: Completed Phase 2 study of Lactation Suppressed, sponsored by Stanford University.
NCT04701333 is a Phase 2 study of Lactation Suppressed that has completed, run by Stanford University. The registered enrollment target is 73 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04701333, a Phase 2 study of Lactation Suppressed, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study investigates the use of a drug, cabergoline, given immediately after second-trimester abortion or perinatal loss to decrease breast engorgement. Cabergoline is a medication approved for the symptomatic treatment of pituitary adenomas that result in a hyperprolactinemic state (a brain tumor that results in milk leakage). The benefit of stopping milk leakage has also been studied and used in populations who shouldn't breastfeed. The investigators aim to clarify if cabergoline is effective in preventing breast engorgement and milk leakage after second-trimester abortions or perinatal loss (stillbirth). Breast engorgement causes physical pain and emotional distress as lactation is uniquely associated with parenthood and those undergoing second-trimester abortions are doing so because they choose not to parent or a previously desired pregnancy is now complicated by anomalies. As there are no current recommendations for management of this painful engorgement beyond icepacks and support bras, the investigators aim to validate the use of this pharmacologic option in this setting.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cabergoline 1 MG
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04701333
The ClinicalTrials.gov registry entry for NCT04701333 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lactation Suppressed appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04701333 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04701333 about?
NCT04701333 is a clinical study titled "Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss". This research study investigates the use of a drug, cabergoline, given immediately after second-trimester abortion or perinatal loss to decrease breast engorgement. Cabergoline is a medication approved for the symptomatic treatment of pituitary adenomas that result in a hyperprolactinemic state (a b...
What is the current status of trial NCT04701333?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2021-04-01. Estimated completion is 2023-03-01.
What conditions does trial NCT04701333 study?
This clinical trial studies the following conditions: Lactation Suppressed.
What interventions are being tested in trial NCT04701333?
The interventions under investigation include: Placebo (DRUG), Cabergoline 1 MG (DRUG).
Who is sponsoring clinical trial NCT04701333?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04701333 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lactation Suppressed
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.